Clinical Trial: NCT05740566
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2026-01-05 |
Study Overview
Brief Summary
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Official Title
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Conditions
Small Cell Lung Cancer (SCLC)
Intervention / Treatment
- Drug: Tarlatamab
- Drug: Lurbinectedin
- Drug: Topotecan
- Drug: Amrubicin
Other Study ID Numbers
- 20210004
Start Date (Actual)
2023-05-31
Primary Completion Date (Actual)
2025-01-29
Study Completion Date (Estimated)
2028-03-26
Enrollment (Actual)
509
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2026-01-05 |
Study Overview
Brief Summary
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Official Title
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Conditions
Small Cell Lung Cancer (SCLC)
Intervention / Treatment
- Drug: Tarlatamab
- Drug: Lurbinectedin
- Drug: Topotecan
- Drug: Amrubicin
Other Study ID Numbers
- 20210004
Start Date (Actual)
2023-05-31
Primary Completion Date (Actual)
2025-01-29
Study Completion Date (Estimated)
2028-03-26
Enrollment (Actual)
509
Study Type
Interventional
Phase
Phase 3